2025

Lenacapavir injectable PrEP approved in Europe

26 August 2025. Related: Antiretrovirals, HIV prevention and transmission.

IAS 2025: Limited access to CD4 tests misses late diagnoses and advanced HIV disease (AHD)

8 August 2025. Related: Conference reports, Treatment strategies, Guidelines, Coinfections and complications.

IAS 2025: Induced stress can increase HIV dynamics

7 August 2025. Related: Conference reports, Cure-related research, Basic science and immunology.

Switching to long-acting injectable ART with detectable viral load in people struggling with oral ART

6 August 2025. Related: Antiretrovirals, Treatment strategies, Drug resistance.

Featured IAS 2025: WHO major updates on injectables, AHD, breastfeeding, infant prophylaxis and peer support

2 August 2025. Related: Conference reports, Guidelines.

13th IAS Conference on HIV Science (IAS 2025): Introduction and early reports

31 July 2025. Related: Conference reports, Activism & advocacy.

IAS 2025: The Kigali Manifesto on the inclusion of people living with HIV in clinical research

31 July 2025. Related: Conference reports, Treatment access, Coinfections and complications, Cancer and HIV, Activism & advocacy, Research studies.

Latest news on US crisis (24 July): Plans to end PEPFAR

29 July 2025. Related: Treatment access, Activism & advocacy.

IAS 2025: Switching to injectable CAB/RPV-LA with detectable viral load: results from the OPERA cohort

28 July 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.

IAS 2025: Switching to dual ART after durable suppression on triple-drug ART in West and Central Africa

27 July 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.

People living with HIV still excluded from 75% of pivotal cancer studies

27 July 2025. Related: Early access, Cancer and HIV.

IAS 2025: Increases in reports of HIV criminalisation cases globally

26 July 2025. Related: Conference reports, Activism & advocacy.

Plans to transition US HIV treatment guidelines (DHHS)

25 July 2025. Related: Guidelines.

Lenacapavir on track for PrEP approval in Europe: questions on access

25 July 2025. Related: Early access, Antiretrovirals, HIV prevention and transmission.

IAS 2025: Once-weekly oral ART with ulonivirine plus islatravir: 24-week phase 2 results

20 July 2025. Related: Conference reports, Antiretrovirals.

IAS 2025: Reduced dosing could be a safe option for adults: crisis response to ART stock-outs

17 July 2025. Related: Conference reports, Treatment strategies.

IAS 2025: 5-on 2-off dosing is inferior to continuous ART in BREATHER Plus – but no differences in clinical outcomes

17 July 2025. Related: Conference reports, Treatment strategies.

IAS 2025: Long-acting CAB/RPV in people with suboptimal adherence: IMPALA study results at 48 weeks

17 July 2025. Related: Conference reports, Antiretrovirals, Drug resistance.

IAS 2025: Once-monthly oral PrEP using MK-8527: the drug that could stop HIV

17 July 2025. Related: Conference reports, Treatment strategies.

Signal that sliver of PEPFAR might be salvaged

16 July 2025. Related: Treatment access, Activism & advocacy.

IAS 2025: “We will not be erased” – a community Call to Action

15 July 2025. Related: Conference reports, Treatment access, Activism & advocacy.

Call to drop abacavir from use in adults

13 July 2025. Related: Journal scan, Antiretrovirals, Treatment strategies, Coinfections and complications.

IAS 2025: HIV care is political: early focus on the funding crisis

12 July 2025. Related: Conference reports, Treatment access.

IAS 2025: HIV cure research at IAS 2025

12 July 2025. Related: Conference reports.

Global Fund plans for lenacapavir PrEP in selected countries

9 July 2025. Related: Treatment access, HIV prevention and transmission.

Featured AIDS quilts at the Tate: reflection and call for action

8 July 2025. Related: In memory, Early access, Special reports.

US government has altered more than 100 scientific databases since 20 January

5 July 2025. Related: Early access, Treatment alerts, Activism & advocacy.

Latest news on US crisis (3 July): legal challenges, Global Fund, WHO, Kigali conference

5 July 2025. Related: Treatment access, Activism & advocacy.

Phase 2/3 studies put on hold for two once-weekly Gilead compounds

3 July 2025. Related: Antiretrovirals.

UK PrEP 2025 guidelines online

2 July 2025. Related: Guidelines, HIV prevention and transmission.

Why the new HIV PrEP guidelines from the UK are so exciting (2025)

2 July 2025. Related: Special reports, Guidelines, HIV prevention and transmission.

Latest on US crisis (26 June): Global Fund, GAVI and RFK Jr

2 July 2025. Related: Treatment access, Activism & advocacy.

Long-acting injectable PrEP approved in the US: priced at $28,000 a year

1 July 2025. Related: Antiretrovirals, HIV prevention and transmission.

Future meetings and webinars 2025

1 July 2025. Related: Future meetings.

Latest on US crisis (13 June): legal and organisational responses

1 July 2025. Related: Treatment access, Activism & advocacy.

HIV organisations support trans and non-binary communities against the unworkable EHRC guidance

1 July 2025. Related: Treatment access, Activism & advocacy.

Featured UK HIV care for transgender and non-binary people: EHRC guidance is unworkable

1 July 2025. Related: Special reports, Treatment access, Activism & advocacy.

IAS 2025: Kigali Call to Action: sign-on to global leaders

1 July 2025. Related: Conference reports.

UK guidelines on doxyPEP to prevent syphilis and gonorrhoea vaccine to become available in England

17 June 2025. Related: Guidelines, Coinfections and complications.

APBI calls for greater participant diversity in industry studies 

15 June 2025. Related: Activism & advocacy, Research studies.

Risk of metabolic syndrome when starting ART with bictegravir vs dolutegravir

7 June 2025. Related: Journal scan, Side effects, Weight, diabetes, metabolic complications.

TAG challenges HIV vaccine cuts as Robert F. Kennedy fires entire CDC vaccine expert advisory panel

6 June 2025. Related: Treatment access, Activism & advocacy, Research studies.

Gates Foundation commits to providing lenacapavir as PrEP next year

3 June 2025. Related: Treatment access, HIV prevention and transmission.

Featured Latest news on the US crisis and its impact on global health

1 June 2025. Related: Journal scan, Special reports, Treatment access, Activism & advocacy.

IAS-USA update drug resistance mutations (2025)

29 May 2025. Related: Guidelines, Drug resistance.

Vaccination is effective in limiting mpox progression – but lower efficacy in people living with HIV

27 May 2025. Related: Journal scan, mpox.

US updates guidelines for statin use in people living with HIV

26 May 2025. Related: Guidelines, Weight, diabetes, metabolic complications.

HIV activists in the US call for action in JID and Zachie Achmat brings South African perspective in the Lancet

26 May 2025. Related: Journal scan, Treatment access, Activism & advocacy.

Combining injectable lenacapavir and cabotegravir-LA

23 May 2025. Related: Journal scan, Antiretrovirals, Treatment strategies, Treatment access.

Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement

22 May 2025. Related: Treatment access, Activism & advocacy, Research studies.

Impact of US funding cuts in Malawi and South Africa: ITPC community report

20 May 2025. Related: Treatment access, On the web.

The Denver Principles – riso print by Jane Shepherd to support i-Base

17 May 2025. Related: Special reports.

US CDC updated guidelines on PEP (May 2025)

10 May 2025. Related: Guidelines, HIV prevention and transmission.

Featured Reduced dosing: a possible crisis response to ART stockouts and closed clinics

5 May 2025. Related: Special reports, Antiretrovirals, Treatment strategies, Treatment access.

Closed clinics and limited ART in Zimbabwe, PEPFAR and UNAIDS news

4 May 2025. Related: Treatment access, Activism & advocacy.

Yellow card reporting scheme for doctors and patients in the UK

1 May 2025. Related: Side effects.

The RIO study: Q&A about controlling HIV with bNAbs

21 April 2025. Related: Conference reports, Cure-related research.

Lenacapavir EAP in the UK closed to new referrals: NHS England and Gilead fail to agree a price after more than two years

20 April 2025. Related: Antiretrovirals, Treatment access, Drug resistance, BHIVA news.

CROI 2025: Webcasts and other resources now open access

16 April 2025. Related: Conference reports.

Continued reports from CROI 2025

13 April 2025. Related: Conference reports.

Viral failure on CAB/RPV-LA: overcoming drug resistance with second-generation INSTIs

13 April 2025. Related: Journal scan, Treatment strategies, Drug resistance.

CROI 2025: LAPTOP, EC rebounds after 32 years, two more HSCT cures

12 April 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.

Lancet Commission on gender justice and equality

9 April 2025. Related: Journal scan.

Changes to US policy jeopardises the lives of 500,000 children living with HIV by 2030

8 April 2025. Related: Treatment access.

CROI 2025: Rebecca Denison gives opening community talk on 40 years of HIV

7 April 2025. Related: Conference reports, Activism & advocacy.